MESO

Insider Trades

Name	Value	Action	Price	Current Price
George GregoryDirector, 10 Percent Owner: $3.4M2.3M shares BuyApr 10, 2026 $1.48 --
George GregoryDirector, 10 Percent Owner: $5.7M4M shares BuyApr 4, 2026 $1.42 --
George GregoryDirector, 10 Percent Owner: $1.3M886.9k shares BuyApr 9, 2026 $1.43 --
George GregoryDirector, 10 Percent Owner: $7.2M500k shares BuyApr 9, 2026 $14.39 --
George GregoryDirector, 10 Percent Owner: $144k10k shares BuyApr 9, 2026 $14.40 --
George GregoryDirector, 10 Percent Owner: $69k4.8k shares BuyApr 9, 2026 $14.40 --

News

globenewswire.comMesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Millionglobenewswire.comApr 29

globenewswire.comMesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Painglobenewswire.comApr 28

globenewswire.comMesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Productsglobenewswire.comApr 14

gurufocus.comFirst Look: JPM beats, RVMD surges, NXST-TGNA pausedgurufocus.comApr 14

Trade MESO

About Mesoblast Limited

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

CEO: Silviu Itescu
IPO Date: Jan 20, 2010

Market Data

Open: $14.35
High: $14.57
Low: $14.19
Volume: 124.9K
Avg Volume: 207.5K
52W High: $21.50
52W Low: $9.88

Valuation

Market Cap: $1.9B
Enterprise Value: $1.9B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-51M
Revenue: $17M
Net Income: $-102M
Cash: $161M
Debt: $128M

Events

EarningsSep 2

EPS est. -0.06